Skip to main content
Corterve
10 Studies Recruiting

Clinical Trials Near New Delhi, India

Find research studies actively recruiting participants near New Delhi. Studies are run at established research institutions including AIIMS and Rajiv Gandhi Cancer Institute.

Top Research Institutions in New Delhi

1

AIIMS

2

Rajiv Gandhi Cancer Institute

3

Max Super Speciality Hospital

Recruiting Studies Near New Delhi

#1

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

RECRUITINGPHASE2, PHASE3Pfizer

Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ductal adenocardinoma.

📍 Birmingham, Alabama📍 Birmingham, Alabama📍 Phoenix, Arizona
#2

Global Trial in APG2575 for Patients With CLL/SLL

RECRUITINGPHASE3Ascentage Pharma Group Inc.

This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors

📍 Tuscon, Arizona📍 Anaheim, California📍 Jacksonville, Florida
#3

A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

RECRUITINGPHASE3Boehringer Ingelheim

This study aims to find out whether a study medicine called survodutide helps people control their blood sugar. Adults who live with type 2 diabetes and with a body mass index (BMI) of 23 kg/m2 or higher can join. The study has 3 parts. In each part the study compares survodutide with placebo. Survodutide is being developed to treat several health problems including type 2 diabetes. Placebo looks like survodutide but does not contain any medicine. Depending on a person's diabetes treatment, a person will be assigned either to * Part A: healthy eating and physical activity * Part B: diabetes tablets (no injection of insulin) * Part C: injection of insulin (with or without diabetes tablets) Participants are randomly put into 1 of 3 groups, which means the group is chosen by chance. Two groups of participants get survodutide at different dose levels, and the third group gets placebo as injection under the skin once a week. You have a 2 in 3 chance of getting survodutide. During the study, participants continue their regular diabetes treatment. Participants are in the study for about 1 year and 2 months. During this time, they attend up to 12 visits at the site and receive at least 9 phone calls. Study doctors regularly test participants' blood sugar by checking their HbA1c values and other laboratory test results. The study doctor also regularly checks participants' health and takes note of any changes. For each study part, the results will be compared between the survodutide and the placebo group to see whether the treatment works.

📍 Birmingham, Alabama📍 Paradise Valley, Arizona📍 Phoenix, Arizona
#4

Effect of Yoga in Chronic Insomnia

RECRUITINGNAAll India Institute of Medical Sciences

This study will evaluate the effect of the yoga in participants with chronic insomnia. The primary objective is to determine whether adding yoga to standard care improves insomnia severity, as measured by the Insomnia Severity Index (ISI), compared to standard care alone. The study will also assess changes in sleep architecture using polysomnography and examine dysfunctional beliefs and attitudes about sleep. Secondary objectives include evaluating the effects of yoga on stress biomarkers (salivary cortisol and salivary alpha-amylase) and on somatosensory information processing using quantitative sensory testing. These measures aim to explore possible mechanisms by which yoga may influence insomnia symptoms, including stress modulation and sensory processing changes. This assessor-blinded, randomized controlled trial will enroll 72 participants aged 18-65 years diagnosed with chronic insomnia. Participants will be randomly assigned to one of three groups: (1) Yoga + Standard Care (2) Stretching group + Standard Care (3) Standard Care alone. The yoga group and stretching group will receive an 8-week intervention (2 weeks supervised group sessions, followed by 6 weeks home practice with telemonitoring). Assessments will be performed at baseline, 2 weeks, and 8 weeks. The primary outcome is change in ISI score at 8 weeks. Secondary outcomes include polysomnographic measures, dysfunctional beliefs and attitudes about sleep, depression-anxiety-stress scores, daytime sleepiness, stress biomarker levels, and sensory thresholds

📍 New Delhi, National Capital Territory of Delhi
#5

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

RECRUITINGPHASE3Novartis Pharmaceuticals

The purpose of this trial is to evaluate whether treatment with pelabresib in combination with ruxolitinib leads to improved clinical outcomes compared to ruxolitinib alone in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) who have not previously received Janus kinase (JAK) inhibitor therapy.

📍 New Haven, Connecticut📍 Fort Myers, Florida📍 Jupiter, Florida
#6

Music Therapy for Rehabilitation in Post-stroke Non-fluent Aphasia: the Indian Adaptation

RECRUITINGNAAll India Institute of Medical Sciences

The goal of this Interventional Study is to develop and test the Indian Adaptation of Melodic Intonation Therapy (MIT) for Indian patients in with post-stroke Non-Fluent Aphasia (PSNFA). The main question\[s\] it aims to answer are: • To develop the MIT Indian Adaptation tool and check its feasibility • To compare the MIT with standard speech rehabilitation in patient with PSNFA. Participants will undergo Speech Rehabilitation according to the developed module and the standard treatment will be given in the comparator arm. The speech recovery at 12 weeks will be compared in both treatment arms.

📍 Delhi, National Capital Territory of Delhi📍 New Delhi, National Capital Territory of Delhi📍 New Delhi, National Capital Territory of Delhi
#7

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

RECRUITINGPHASE2, PHASE3Pfizer

The purpose of this clinical trial is to learn about the effects and safety of the study medicine PF-07275315 for the potential treatment of COPD. COPD is a condition that makes it difficult to breathe, which negatively impacts the quality of life and functioning of people who are affected. This study is seeking participants who: * Are 35 to 80 years old * Have had moderate-to-severe COPD for at least 12 months * Have a documented history of at least 2 moderate or severe exacerbations within the last 12 months * Have been continuously taking their regular maintenance treatment(s) for COPD over at least 6 months at a stable dose for 3 months All participants will receive PF-07275315 or a placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. PF-07275315 or placebo will be given as multiple shots in the clinic over the course of 24 weeks for the Phase 2 part and 52 weeks for the Phase 3 part. We will compare the results of people receiving PF-07275315 to those of the people who do not. This will help us determine if PF-07275315 is safe and effective. Participants who will be involved in the Phase 2 part of the study for about 40 weeks. During this time, they will have 11 visits at the study clinic. Participants who will be involved in the Phase 3 part of the study for about 68 weeks. During this time, they will have 18 visits at the study clinic.

📍 Birmingham, Alabama📍 Dothan, Alabama📍 Mobile, Alabama
#8

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)

RECRUITINGPHASE3Azafaros B.V.

An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick type C disease

📍 Oakland, California📍 Minneapolis, Minnesota📍 Rochester, Minnesota
#9

Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study

RECRUITINGNot SpecifiedFriedreich's Ataxia Research Alliance

This project is a global, multicenter, prospective, longitudinal, observational natural history study that can be used to understand the disease progression and support the development of safe and effective drugs and biological products for Friedreich ataxia.

📍 Los Angeles, California📍 Denver, Colorado📍 Gainesville, Florida
#10

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

RECRUITINGPHASE3Novartis Pharmaceuticals

The purpose of this study is to provide efficacy and safety data for remibrutinib in patients with secondary progressive multiple sclerosis (SPMS)

📍 Birmingham, Alabama📍 Phoenix, Arizona📍 Phoenix, Arizona

Clinical Trials in New Delhi: FAQ

How do I find clinical trials near New Delhi?

Corterve aggregates all actively recruiting clinical trials near New Delhi, India from the ClinicalTrials.gov database. Simply browse the listings on this page or take our assessment to find trials that may be relevant.

Does it cost anything to take part in a study?

Costs, travel support, and any payment for taking part vary by study. Ask the study team what is covered before you decide to join.

What research institutions are located in New Delhi?

New Delhi is home to several leading research institutions, including AIIMS, Rajiv Gandhi Cancer Institute, Max Super Speciality Hospital. These facilities run clinical trials across Oncology, Neurology, Cardiology, and other therapeutic areas.

Ready to see studies near you?

Take our assessment to see research studies recruiting near New Delhi that may be relevant. Study teams decide who joins.

See studies near you